Specialty Vaccine Company PaxVax Appoints Jim Connolly to Board of Directors

Industry Veteran Joins Company as it Readies for the Anticipated Commercial Launch of its Cholera Vaccine for Travelers

Redwood City – APRIL 29, 2014 – PaxVax Inc., a specialty vaccine company focused on travelers and biodefense markets with a social mission to ensure global access to its vaccines, today announced the appointment of Jim Connolly to its Board of Directors. Connolly joins current Board members Rennie Coit, M.D., and Rich Tong from Ignition Capital; retired Major General Philip K. Russell, M.D.; Howie Rosen; and PaxVax Chief Executive Officer Kenneth Kelley.

Pages

Cholera

18.97
-72.29

Anthrax

40.71
-74.01

Typhoid

21.00
78.00

Hepatitis A

39.92
32.83

H5N1, Dengue

& HIV

-0.78
113.92

for protection wherever you are and wherever you go

PaxVax is a fully integrated specialty vaccine company committed to developing and commercializing innovative vaccines against infectious diseases.

PaxVax: Better Vaccines

37.44
-122.14
Subscribe to PaxVax - Socially Responsible Vaccines RSS